Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab in Metastatic HER2+ Breast Cancer
NCT03125928Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2017
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in HER2-positive breast cancer, sponsored by Fox Chase Cancer Center. Primary endpoints: Number of participants with treatment-related adverse events at 5 years and Antitumor activity of atezolizumab plus the standard regimen at 18 weeks. Started Jun 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03125928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125928.